CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · USHealthcareBiotechnology
$13.53-4.92%
Price as of Jul 20, 2026
CTNM financials
Contineum Therapeutics, Inc. Class A Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $50.0M | $0.00 |
| Cost of revenue | $0.00 | $258.0K | $0.00 | $0.00 |
| Gross profit | $0.00 | -$258.0K | $50.0M | $0.00 |
| Operating expenses | $68.1M | $50.6M | $66.1M | $22.7M |
| Operating income | -$68.1M | -$50.9M | -$16.1M | -$22.7M |
| Net income | -$60.0M | -$42.3M | $22.7M | -$24.3M |
| EBITDA | -$59.7M | -$42.0M | $23.6M | -$23.5M |
| Basic EPS | $-2.17 | $-1.63 | $0.13 | $-0.97 |
| Diluted EPS | $-2.17 | $-1.63 | $0.13 | $-0.97 |
| Balance sheet | ||||
| Cash & equivalents | $75.6M | $21.9M | $15.5M | $5.6M |
| Total assets | $276.6M | $212.8M | $130.4M | $50.6M |
| Total liabilities | $15.7M | $14.8M | $198.3M | $11.4M |
| Stockholders’ equity | $261.0M | $198.1M | -$67.9M | $39.3M |
| Total debt | $8.3M | $6.3M | $193.2M | $5.8M |
| Net debt | -$67.4M | -$15.7M | $177.7M | $280.0K |
| Cash flow | ||||
| Operating cash flow | -$55.3M | -$32.8M | $19.3M | -$20.1M |
| Capital expenditure | -$231.0K | -$514.0K | -$414.0K | -$118.0K |
| Free cash flow | -$55.5M | -$33.4M | $18.9M | -$20.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$28.0K | -$4.0K |